Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder Cancers

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Media: Internet - based


Activity Overview

This Clinical Interchange™ features an expert panel discussion of noteworthy clinical data on immune checkpoint inhibitors. Practice-changing data and emerging immunotherapeutic strategies for cancers of the lung, head and neck, and bladder are summarized, along with expert discussions on the clinical application of these data and the evolving landscape of selective biomarkers. This program also includes a case-based discussion on the management of immune-related adverse events.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

CME Activity Table of Contents

  • Introduction and Background of Immunotherapy
  • Segment 1: Evolving Treatment Paradigms With the Use of Immuno-Oncology Strategies for the Management of Non–Small Cell Lung Cancer
  • Segment 2: Clinical Applications of Immuno-Oncology in the Multimodal Management of Head and Neck Squamous Cell Carcinoma
  • Segment 3: How Immuno-Oncology Strategies Are Changing Treatment Paradigms in Bladder Cancer
  • Segment 4: What Have We Learned About the Biomarkers and Resistance?
  • Segment 5: Case-Based Panel Discussion: Managing Patients and Toxicities/Closing Remarks

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CMEcertificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals are also invited to participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain clinically unmet needs in the management of non–small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer
  • Describe how the immune system can be harnessed to treat cancer and the mechanistic rationale for the application of checkpoint inhibition strategies to target specific solid tumors
  • Interpret recent findings from clinical trials conducted with immuno-oncology strategies for the treatment of lung cancer, HNSCC, and bladder cancer
  • Describe the current status of biomarkers as a method to personalize care with the use of immuno-oncology strategies
  • Evaluate methods to mitigate treatment-related toxicities via proactive mitigation and management of immune-related adverse events (irAEs)

Faculty, Staff, and Planners' Disclosures


Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: Grant/Research Support: Genentech, Merck. Consultant: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer


Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosure: Grant/Research Support: Millennium, Celgene, Merck. Consultant: BMS, Lilly, Pfizer, AstraZeneca, Novartis, Celgene, Genentech, EMD-Serono, Merck, Trovagene. Other Support: DSMB for University of Pennsylvania.

Daniel Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology
Co-Director, Signal Transduction Research Program
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosure: Grant/Research Support: Oncogenix, Progenics, Johnson & Johnson, Merck, Millennium, Celgene, Dendreon, Sanofi, Agensys, Eli Lilly, Roche Laboratories. Consultant: Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyrne Pharmaceuticals. Stock/ Shareholder: Bellicum, Tyme

Tanguy Seiwert, MD
Medical Oncologist
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

Disclosure: Honoraria: Amgen, AstraZeneca, BMS, Eisai, Eli Lilly, Merck, EMD-Serono, Innate, Jounce

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CMEactivities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CMEactivity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CMEactivity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By